Table 1. Baseline Characteristics and Follow-up Duration for the Total Cohort.
| Characteristica | Group Receiving Off-label Rituximab Treatment | Control Group | P Valueb |
|---|---|---|---|
| Before propensity score matching | |||
| No. of patients | 54 | 59 | |
| Age, y | |||
| Mean (SD) | 49.0 (9.6) | 53.5 (8.0) | .008 |
| Median (range) | 49.0 (23.0-71.0) | 54.0 (37.0-70.0) | |
| Female, No. (%) | 32 (59) | 33 (56) | .85 |
| Disease duration, y | |||
| Mean (SD) | 18.6 (9.3) | 18.8 (9.0) | .97 |
| Median (range) | 18.0 (3.0-40.0) | 18.0 (3.0-45.0) | |
| EDSS BL | |||
| Mean (SD) | 6.02 (1.32) | 5.21 (1.47) | .002 |
| Median (range) | 6.25 (2.50-8.50) | 5.50 (2.00-8.00) | |
| Follow-up, mo | |||
| Mean (SD) | 42.3 (31.4) | 64.3 (29.4) | <.001 |
| Median (range) | 33.9 (6.6-111.4) | 59.9 (12.2-123.5) | |
| Follow-up, y | |||
| Mean (SD) | 3.5 (2.6) | 5.4 (2.4) | |
| Median (range) | 2.8 (0.6-9.3) | 5.0 (1.0-10.3) | |
| After propensity score matching | |||
| No. of patients | 44 | 44 | |
| Age, y | |||
| Mean (SD) | 49.7 (10.0) | 51.3 (7.4) | .36 |
| Median (range) | 50.0 (23.0-71.0) | 50.5 (37.0-65.0) | |
| Female, No. (%) | 26 (59) | 27 (61) | >.99 |
| Disease duration, y | |||
| Mean (SD) | 18.2 (9.4) | 19.4 (8.7) | .45 |
| Median (range) | 17.0 (3.0-40.0) | 19.5 (3.0-35.0) | |
| EDSS BL | |||
| Mean (SD) | 5.93 (1.40) | 5.70 (1.29) | .28 |
| Median (range) | 6.00 (2.50-8.50) | 6.00 (2.50-8.00) | |
| Follow-up, mo | . | ||
| Mean (SD) | 41.8 (32.2) | 57.7 (26.5) | 002 |
| Median (range) | 29.8 (6.6-111.4) | 54.5 (12.2-112.3) | |
| Follow-up, y | |||
| Mean (SD) | 3.5 (2.7) | 4.8 (2.2) | |
| Median (range) | 2.5 (0.6-9.3) | 4.5 (1.0-9.4) |
Abbreviation: EDSS BL, Expanded Disability Status Scale score after baseline.
a
Number and percentage of patients with measurements are given for categorical variables; mean (SD) and median (range) are given for continuous and ordinal variables.
b
Derived from Fisher exact tests (categorical) and from Wilcoxon rank sum tests (Mann-Whitney tests, continuous). For standardized differences between groups before and after propensity score matching, see eTable 1 in the Supplement.